All In Biotech

Free tool

FAERS Monitor: Fulphila

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761075 or its brand name (Fulphila, Pegfilgrastim-Jmdb). Reports on generic versions are filed under their own applications.

Reports

452

Serious

294

65% of reports

Hospitalization

146

Death reported

86

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death70
  • off label use29
  • drug ineffective25
  • nausea25
  • febrile neutropenia22
  • neutropenia22
  • product quality issue21
  • diarrhoea18
  • hospitalisation18
  • vomiting18
  • device leakage17
  • pyrexia17
  • needle issue15
  • fatigue13
  • product dose omission issue13

Reports by year received

View as table
YearReports
201810
201929
202040
202152
202237
202353
2024108
202595
202628

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,707 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
needle issueSignal1524.014.6308
device leakageSignal1718.311.4261
febrile neutropeniaSignal2215.410.3284
neutropeniaSignal227.55.0119
product quality issueSignal217.24.7107
hospitalisationSignal185.53.562
deathSignal703.83.0146
pyrexiaSignal172.31.411
product dose omission issueSignal132.11.26
vomiting181.81.16
off label use291.51.15
nausea251.51.03
diarrhoea181.30.81
drug ineffective250.90.60
fatigue130.80.51

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.